Clinical and commercial wins mark turning point as GSK ups outlook

26 July 2023
gsk_london_hq

Sales and profits at GSK (LSE: GSK) beat expectations in the second quarter of 2023, with the firm reporting respectively a 4% and 8% increase from the same period of last year.

Britain’s second-largest drugmaker took in £7.2 billion ($9.2 billion) sales for the period, with £2.2 billion in profit, leading to an adjusted earnings per share (EPS) result of £0.38.

Headquartered in West London, GSK has a broad range of products, with particular expertise in vaccines, respiratory conditions and medicines for HIV.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical